Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 16 studies | 24% ± 9% | |
astrocyte | 12 studies | 27% ± 8% | |
adipocyte | 11 studies | 53% ± 16% | |
smooth muscle cell | 9 studies | 28% ± 8% | |
pericyte | 8 studies | 30% ± 11% | |
endothelial cell | 7 studies | 24% ± 7% | |
extravillous trophoblast | 3 studies | 26% ± 8% | |
hepatocyte | 3 studies | 46% ± 29% |
Insufficient scRNA-seq data for expression of ANGPTL4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 97% | 8274.57 | 219 / 226 | 89% | 141.78 | 362 / 406 |
thymus | 90% | 3133.83 | 588 / 653 | 74% | 63.45 | 446 / 605 |
pancreas | 73% | 3319.86 | 240 / 328 | 75% | 103.55 | 134 / 178 |
lung | 76% | 3817.36 | 442 / 578 | 58% | 51.07 | 675 / 1155 |
breast | 98% | 14221.56 | 448 / 459 | 37% | 21.97 | 413 / 1118 |
skin | 77% | 2874.35 | 1401 / 1809 | 54% | 48.79 | 256 / 472 |
kidney | 54% | 3836.29 | 48 / 89 | 71% | 664.80 | 643 / 901 |
bladder | 62% | 2095.52 | 13 / 21 | 59% | 56.46 | 299 / 504 |
brain | 58% | 2227.76 | 1532 / 2642 | 56% | 43.62 | 395 / 705 |
esophagus | 64% | 1947.74 | 930 / 1445 | 39% | 19.85 | 72 / 183 |
prostate | 64% | 2461.82 | 157 / 245 | 36% | 15.39 | 183 / 502 |
ureter | 0% | 0 | 0 / 0 | 100% | 28.94 | 1 / 1 |
adipose | 100% | 16514.28 | 1199 / 1204 | 0% | 0 | 0 / 0 |
adrenal gland | 67% | 1665.27 | 172 / 258 | 27% | 19.85 | 62 / 230 |
uterus | 16% | 328.94 | 28 / 170 | 63% | 62.19 | 287 / 459 |
tonsil | 0% | 0 | 0 / 0 | 76% | 48.92 | 34 / 45 |
intestine | 56% | 1563.98 | 544 / 966 | 19% | 9.38 | 98 / 527 |
blood vessel | 70% | 3458.71 | 936 / 1335 | 0% | 0 | 0 / 0 |
stomach | 48% | 1359.28 | 174 / 359 | 15% | 9.57 | 42 / 286 |
ovary | 23% | 617.04 | 42 / 180 | 32% | 14.20 | 138 / 430 |
heart | 52% | 1902.70 | 447 / 861 | 0% | 0 | 0 / 0 |
muscle | 40% | 1015.67 | 325 / 803 | 0% | 0 | 0 / 0 |
spleen | 39% | 863.98 | 95 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 24% | 11.17 | 7 / 29 |
peripheral blood | 3% | 60.18 | 27 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.33 | 1 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0072577 | Biological process | endothelial cell apoptotic process |
GO_0070328 | Biological process | triglyceride homeostasis |
GO_0001525 | Biological process | angiogenesis |
GO_2000352 | Biological process | negative regulation of endothelial cell apoptotic process |
GO_0051005 | Biological process | negative regulation of lipoprotein lipase activity |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0006629 | Biological process | lipid metabolic process |
GO_0043335 | Biological process | protein unfolding |
GO_0001666 | Biological process | response to hypoxia |
GO_0045766 | Biological process | positive regulation of angiogenesis |
GO_0005615 | Cellular component | extracellular space |
GO_0072562 | Cellular component | blood microparticle |
GO_0005576 | Cellular component | extracellular region |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0004857 | Molecular function | enzyme inhibitor activity |
GO_0005515 | Molecular function | protein binding |
GO_0042802 | Molecular function | identical protein binding |
Gene name | ANGPTL4 |
Protein name | Angiopoietin like 4 Angiopoietin-related protein 4 (Angiopoietin-like protein 4) (Hepatic fibrinogen/angiopoietin-related protein) (HFARP) [Cleaved into: ANGPTL4 N-terminal chain; ANGPTL4 C-terminal chain] |
Synonyms | PGAR UNQ171/PRO197 PSEC0166 PP1158 HFARP ARP4 |
Description | FUNCTION: Mediates inactivation of the lipoprotein lipase LPL, and thereby plays a role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism . May also play a role in regulating glucose homeostasis and insulin sensitivity (Probable). Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage . Upon heterologous expression, inhibits the adhesion of endothelial cell to the extracellular matrix (ECM), and inhibits the reorganization of the actin cytoskeleton, formation of actin stress fibers and focal adhesions in endothelial cells that have adhered to ANGPTL4-containing ECM (in vitro) . Depending on context, may modulate tumor-related angiogenesis (By similarity). .; FUNCTION: [ANGPTL4 N-terminal chain]: Mediates inactivation of the lipoprotein lipase LPL, and thereby plays an important role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism . Has higher activity in LPL inactivation than the uncleaved protein . . |
Accessions | M0R3A2 ENST00000601886.1 ENST00000601770.1 M0QZ51 ENST00000593998.5 [Q9BY76-1] M0R369 M0R0N8 Q9BY76 ENST00000595079.5 M0R2X8 ENST00000599192.5 ENST00000301455.7 [Q9BY76-1] ENST00000594875.1 ENST00000393962.6 [Q9BY76-2] |